669 results on '"Bertotti, Andrea"'
Search Results
2. DNA demethylation triggers cell free DNA release in colorectal cancer cells
3. XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients
4. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
5. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification
6. The biomedicalization of pregnancy prevention, neoliberal feminism, and college women's experiences of the contraceptive paradox
7. Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
8. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity
9. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
10. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
11. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
12. Effective drug combinations in breast, colon and pancreatic cancer cells
13. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin
14. The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization
15. How Ignoring the Fundamental Causes of Maternal Morbidity/Mortality Impedes Progress Toward a Reproductive Justice Model of Contraceptive Counseling
16. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
17. Efficacy as safety: Dominant cultural assumptions and the assessment of contraceptive risk
18. DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
19. Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
20. Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
21. Supplementary Table 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
22. Supplementary Table 8 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
23. Supplementary Table 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
24. Supplementary Figure 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
25. Supplementary Table 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
26. Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
27. Supplementary Table 7 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
28. Supplementary Figure 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
29. Supplementary Table 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
30. Supplementary Methods 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
31. Supplementary Figure 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
32. Supplementary Table 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
33. Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
34. Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
35. Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
36. Data from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
37. Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
38. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
39. Adaptive mutability of colorectal cancers in response to targeted therapies
40. Constructing contentious and noncontentious facts : How gynecology textbooks create certainty around pharma-contraceptive safety
41. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
42. PhyliCS: a Python library to explore scCNA data and quantify spatial tumor heterogeneity
43. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
44. Pathway level subtyping identifies a slow-cycling and transcriptionally lethargic biological phenotype associated with poor clinical outcomes in colon cancer independent of genetics
45. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
46. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
47. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
48. Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer
49. DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
50. Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.